Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) was the target of a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 117,900 shares, a decrease of 33.8% from the May 15th total of 178,000 shares. Based on an average trading volume of 1,930,000 shares, the short-interest ratio is currently 0.1 days. Currently, 1.8% of the company’s stock are short sold.

Evogene Stock Performance

NASDAQ EVGN opened at $1.52 on Tuesday. The stock has a 50-day simple moving average of $1.19 and a 200 day simple moving average of $1.38. Evogene has a twelve month low of $0.95 and a twelve month high of $7.19. The stock has a market capitalization of $8.15 million, a PE ratio of -0.34 and a beta of 1.55.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings results on Wednesday, May 21st. The biotechnology company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.12. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The company had revenue of $2.44 million for the quarter, compared to the consensus estimate of $4.42 million.

Hedge Funds Weigh In On Evogene

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC grew its position in Evogene by 5.9% in the 1st quarter. Armistice Capital LLC now owns 316,024 shares of the biotechnology company’s stock worth $395,000 after purchasing an additional 17,743 shares during the last quarter. Jane Street Group LLC grew its position in Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after buying an additional 12,387 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in Evogene during the fourth quarter valued at about $30,000. Institutional investors own 10.40% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on EVGN shares. Alliance Global Partners reaffirmed a “buy” rating on shares of Evogene in a research report on Friday, March 7th. Lake Street Capital set a $3.50 price objective on shares of Evogene and gave the stock a “buy” rating in a report on Thursday, May 22nd. Finally, Wall Street Zen assumed coverage on shares of Evogene in a report on Wednesday, May 21st. They issued a “sell” rating on the stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.